Log in

Relevant bibliographies by topics / ABOi transplant / Journal articles

To see the other types of publications on this topic, follow the link: ABOi transplant.

Journal articles on the topic 'ABOi transplant'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'ABOi transplant.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Xiao, Min, Zhenmiao Wan, Xin Lin, et al. "ABO-Incompatible Liver Transplantation under the Desensitization Protocol with Rituximab: Effect on Biliary Microbiota and Metabolites." Journal of Clinical Medicine 12, no. 1 (2022): 141. http://dx.doi.org/10.3390/jcm12010141.

Full text

Abstract:

Background: ABO-incompatible liver transplantation (ABOi LT) under the desensitization protocol with rituximab had excellent survival outcomes comparable to those of ABO-compatible liver transplantation (ABOc LT). In this work, we explored the effect of ABOi LT on recipients from the perspective of biliary microbiota and metabonomics. Methods: Liver transplant (LT) recipients treated at our center were enrolled in the study. In total, 6 ABOi LT recipients and 12 ABOc LT recipients were enrolled, and we collected their bile five times (during LT and at 2 days, 1 week, 2 weeks and 1 month after

APA, Harvard, Vancouver, ISO, and other styles

2

Pavenski, Katerina, Megan Buchholz, Patti Lou Cheatley, et al. "The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group–Incompatible Kidney Transplantation." Canadian Journal of Kidney Health and Disease 7 (January 2020): 205435812096258. http://dx.doi.org/10.1177/2054358120962586.

Full text

Abstract:

Background: Blood group incompatibility (ABOi) is the most common barrier to living donor kidney transplantation. Options for such recipients include kidney paired donation (KPD) or desensitization methodology to reduce blood antibody response. Objective: The objective of this study is to report on the first North America experience in ABOi living donor kidney transplantation using Glycosorb ABO immunoadsorption columns. Design: Retrospective observational cohort study. Setting: Renal transplant program at St. Michael’s Hospital, Unity Health Toronto, University of Toronto. Patients: Twenty-si

APA, Harvard, Vancouver, ISO, and other styles

3

de Magnée, Catherine, Louise Brunée, Roberto Tambucci, et al. "Is ABO-Incompatible Living Donor Liver Transplantation Really a Good Alternative for Pediatric Recipients?" Children 8, no. 7 (2021): 600. http://dx.doi.org/10.3390/children8070600.

Full text

Abstract:

Background: ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has been proposed to compensate for donor shortage. To date, few studies have reported detailed ABOi LDLT results in large series of pediatric patients. C4d complement deposition in graft capillaries has been reported to be associated with antibody-mediated rejection in solid organ transplantation. Methods: A retrospective case–control study was conducted, comparing clinical outcomes of each of 34 consecutive pediatric ABOi LDLT recipients with those of 2 non-ABOi pairs (n = 68), matched according to pre-transplant d

APA, Harvard, Vancouver, ISO, and other styles

4

Amitkumar, Vishnubhai Prajapati, Vimalbhai Kanodia Kamal, Yuvraj Modi Pooja, Vallabhbhai Patel Himanshu, Bhagwanbhai Vala Kinnari, and Ramanlal Modi Pranjal. "Therapeutic Plasma Exchange as a Pre-Conditioning Regimen in ABO Incompatible Renal Transplant- Experience from Largest Transplant Institute in Gujarat, India." International Journal of Pharmaceutical and Clinical Research 16, no. 12 (2024): 1454–60. https://doi.org/10.5281/zenodo.14613590.

Full text

Abstract:

<strong>Background: </strong>ABO non-identical renal transplantation is becoming increasingly common to overcome the unavailability/ shortage of ABO identical donor(s). This study was conducted to evaluate whether Plasma exchange is an effective method in reducing ABO titers to desired levels in ABO Incompatible renal transplant recipients, as used as a part of desensitization regimen. <strong>Methods: </strong>A retrospective observational analysis was done in 11 patients taken for ABOi renal transplant from February 2022 to April 2024. All the 11 patients were treated with Pla

APA, Harvard, Vancouver, ISO, and other styles

5

Fernando, Meranthi, Suchintha Tillakaratne, Bhagya Gunetilleke, et al. "An ABO-incompatible living donor liver transplant in an infant with acute liver failure in the Sri Lankan setting." Ceylon Medical Journal 68, no. 1 (2023): 25–28. http://dx.doi.org/10.4038/cmj.v68i1.9714.

Full text

Abstract:

Liver transplant (LT) is the standard therapy for medically refractory acute liver failure (ALF). Finding a deceaseddonor graft in an emergency is challenging and often overcome by living-donation. Blood group matching is practised for LT though ABO-incompatible liver transplant (ABOi-LT) is performed inselected circumstances. We report an infant who underwent successful ABOincompatible living donor LT for ALF of unknown aetiology. This being the country’s first ABOi-LT, the youngest LT recipient to date and the youngest receiving emergency LT for ALF; we describe the novel experience at a res

APA, Harvard, Vancouver, ISO, and other styles

6

Lam, Susanna, Sebastian Hultin, John Preston, and Scott Campbell. "Temporal Change in Blood Group after Bone Marrow Transplant: A Case of Successful ABO-Incompatible Deceased Donor Transplant." Case Reports in Transplantation 2020 (July 24, 2020): 1–4. http://dx.doi.org/10.1155/2020/7461052.

Full text

Abstract:

ABO-incompatible kidney transplantation has been successfully utilised in a deceased donor and living donor kidney transplantation to improve organ utilisation and decrease waiting times. We describe a case of a successful, unanticipated ABO-incompatible donation after cardiac death (DCD) kidney transplant in a patient who had a previous ABOi haematopoietic stem cell transplant (HSCT) and had reverted to his original blood group B, after matching as a blood group A recipient with a blood group A donor. The recipient was unsensitized with a cPRA which was 0% and no donor-specific antibodies and

APA, Harvard, Vancouver, ISO, and other styles

7

van Agteren, Madelon, Willem Weimar, Annelies E. de Weerd, et al. "The First Fifty ABO Blood Group Incompatible Kidney Transplantations: The Rotterdam Experience." Journal of Transplantation 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/913902.

Full text

Abstract:

This study describes the single center experience and long-term results of ABOi kidney transplantation using a pretransplantation protocol involving immunoadsorption combined with rituximab, intravenous immunoglobulins, and triple immune suppression. Fifty patients received an ABOi kidney transplant in the period from 2006 to 2012 with a follow-up of at least one year. Eleven antibody mediated rejections were noted of which 5 were mixed antibody and cellular mediated rejections. Nine cellular mediated rejections were recorded. Two grafts were lost due to rejection in the first year. One-year g

APA, Harvard, Vancouver, ISO, and other styles

8

Andenna, Gabriele Gualtiero, Marilena Gregorini, Chiara Elena, et al. "Persistent Neutropenia after ABOi Kidney Transplantation: A Case Report." Transplantology 2, no. 2 (2021): 183–90. http://dx.doi.org/10.3390/transplantology2020017.

Full text

Abstract:

Post-transplant neutropenia (PTN) is frequently reported in the first-year after transplantation. Although prevalence and clinical consequences are widely described, there are no guidelines to manage diagnosis and treatment. We report here a case of persistent PTN occurred in a patient undergoing a kidney transplant from an AB0-incompatible living donor. The desensitization protocol consisted of Rituximab administration and immunoadsorption while the pre-transplant protocol, which was initiated 14 days before the transplant, included Tacrolimus, Mofetil Mycophenolate (MMF), antimicrobial and a

APA, Harvard, Vancouver, ISO, and other styles

9

Markiewicz-Kijewska, Małgorzata, Piotr Kaliciński, Juan Torres Canizales, et al. "ABO Incompatible Liver Transplantation in Children: A 20 Year Experience from Centres in the TransplantChild European Reference Network." Children 8, no. 9 (2021): 760. http://dx.doi.org/10.3390/children8090760.

Full text

Abstract:

An increasing number of AB0-incompatible (AB0i) liver transplantations (LT) are being undertaken internationally in recent years due to organ shortages and the need for urgent transplantation. The aim of our study was establish the value of ABOi LT from available retrospective results of AB0i pediatric liver transplantations performed in European reference centers now belonging to the TransplantChild, European Reference Network (ERN). Data from medical records were analyzed, including demographic data, diagnosis, urgency of transplantation, time on the waiting list, PELD/MELD score, desensitiz

APA, Harvard, Vancouver, ISO, and other styles

10

L, Bahena-Carrera. "Donor exchange programs and ABO incompatible transplant. Change in the traditional view of kidney transplantation in Mexico." Revista de Sanidad Militar 72, no. 2 (2018): 133–40. http://dx.doi.org/10.56443/rsm.v72i2.164.

Full text

Abstract:

There are numerous studies that demonstrate the superiority in terms of survival and quality of life of the transplant as a renal replacement therapy compared with hemodialysis and peritoneal dialysis. National and global waiting lists increase disproportionately in relation to the number of transplants performed and the different governments should institute measures to guarantee the selfsuffi ciency of organs in each country and does the donor Exchange programs and the ABOi resources already tested in different parts of the world with adequate safety and effectiveness that can improve the ra

APA, Harvard, Vancouver, ISO, and other styles

11

Lee, Sangho, Kyoung-Sun Kim, Bo-Hyun Sang, and Gyu-Sam Hwang. "Serious acid-base disorder or life-threatening arrhythmia in patients with ABO-incompatible liver transplantation who received therapeutic plasma exchange - A report of two cases -." Anesthesia and Pain Medicine 17, no. 1 (2022): 57–61. http://dx.doi.org/10.17085/apm.21045.

Full text

Abstract:

Background: Excessive citrate load during therapeutic plasma exchange (TPE) can cause metabolic alkalosis with compensatory hypercarbia and electrolyte disturbances. If TPE is required immediately before ABO-incompatible (ABOi) liver transplant (LT) surgery, metabolic derangement and severe electrolyte disturbance could worsen during LT anesthesia.Case: We report two ABOi LT cases who received TPE on the day of surgery because isoagglutinin titers did not be dropped below 1:8. One case had a surprisingly high metabolic alkalosis with a pH of 7.73 immediately after tracheal intubation because o

APA, Harvard, Vancouver, ISO, and other styles

12

Imran, Mishal, Ubaid ullah Khan, Maham Farooq, et al. "Pioneering in ABO-Incompatible Renal Transplantation in Pakistan: Breaking Barriers – A Case Series." INNOVAPATH 1, Q2 (2025): 2. https://doi.org/10.63501/bmytmk85.

Full text

Abstract:

Background Kidney transplantation is the treatment of choice for end-stage renal disease (ESRD). However, limited donor availability, especially live-related donors, hinders access to this life-saving procedure. ABO-incompatible kidney transplantation (ABOi KT) offers a promising solution to expand the donor pool. This case series presents the first successful ABOi KT cases in Pakistan. Objectives To explore the outcomes of ABO-incompatible renal transplants analyzing graft survival, rejection episodes, and patient outcomes. Methods A retrospective analysis was performed on 15 patients who und

APA, Harvard, Vancouver, ISO, and other styles

13

Tan, S. Y., M. Rao, and E. T. Koh. "Three year results of the pioneer ABOi renal transplant program in Malaysia." Transplantation Reports 1, no. 1-2 (2016): 1–3. http://dx.doi.org/10.1016/j.tpr.2016.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Wyburn, K. R., S. B. Campbell, P. T. Coates, et al. "RESULTS FROM AN AUSTRALIAN NATIONAL ABO INCOMPATIBLE (ABOI) RENAL TRANSPLANT COLLABORATIVE GROUP." Transplantation Journal 90 (July 2010): 270. http://dx.doi.org/10.1097/00007890-201007272-00509.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Maggioni, Sébastien, Eric Faubel, Martine Hermelin, Asma Allal, and Lionel Rostaing. "Immunoadsorption and Its Application for Desensitizing Incompatible Kidney Transplant Candidates Who Have a Potential Living Donor." KIDNEYS, no. 1.07 (February 28, 2014): 18–23. http://dx.doi.org/10.22141/2307-1257.0.1.07.2014.76546.

Full text

Abstract:

Background. Plasmapheresis is widely used to remove potential deleterious antibodies from the blood. Because the volume of treated plasma is limited, plasmapheresis can be replaced by immunoadsorption (IA), a more tedious but sophisticated technique that enables treatment of larger volumes of plasma, i.e., > 4 L vs. 1.5–2 L. We have implemented in our department IA technique to replace plasmapheresis when we launched our ABO-incompatible (ABOi) and HLA-incompatible (HLAi) kidney-transplant programs with living kidney donors. In this setting, isoagglutinin titers (ABOi) or donor-specific all

APA, Harvard, Vancouver, ISO, and other styles

16

Youk, Hee-Jeong, Ho-yoon Ryu, Suk Won Seo, et al. "A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity." Medicina 58, no. 6 (2022): 830. http://dx.doi.org/10.3390/medicina58060830.

Full text

Abstract:

Background and objectives: The ABO antibody (Ab) titration tests are used in monitoring in ABO-incompatible (ABOi) solid organ transplantation (SOT). However, currently developed ABO Ab tests show Ab binding reactions. This study attempted to measure ABO Ab level using complement-dependent cytotoxicity (CDC). Materials and methods: We studied 93 blood group O serum samples from patients who underwent ABOi SOT from January 2019 to May 2021. Patients’ sera were incubated with A1 or B cells and added to a human complement solution. Supernatants were collected after centrifugation, and free hemogl

APA, Harvard, Vancouver, ISO, and other styles

17

S, Sabarinath, Amit Gupta, Manas R. Patel, et al. "Outcomes of Biopsy-Proven Acute Rejection (BPAR) in ABOIncompatible Kidney Transplants (ABOi KTx) Compared with a Propensity-Matched Cohort of ABO-Compatible Transplant Recipients (ABOc KTx)." Journal of the American Society of Nephrology 31, no. 10S (2020): 775–76. http://dx.doi.org/10.1681/asn.20203110s1775c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Venkata, Varsha Reddy Pothula, Karen M. Warburton, Jeanne Kamal, William F. Glass, and Alden M. Doyle. "A Case of Self-Limited Thrombotic Microangiopathy (TMA) After an ABO Incompatible (ABOi) Kidney Transplant (KT)." Journal of the American Society of Nephrology 34, no. 11S (2023): 612. http://dx.doi.org/10.1681/asn.20233411s1612b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Pan, Yipeng, Jicheng Hu, Tao Li, et al. "Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report." Transplant Immunology 85 (August 2024): 102079. http://dx.doi.org/10.1016/j.trim.2024.102079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Berchtold, Caroline, Kerstin Huebel, Fabian Roessler, et al. "The Burden of ABO-Incompatible Kidney Transplantation: Readmission Rates and Complications, a Twenty-Year Analysis." Journal of Clinical Medicine 13, no. 23 (2024): 7477. https://doi.org/10.3390/jcm13237477.

Full text

Abstract:

Background/Objectives: ABO-incompatible live-donor kidney transplantation (ABOi-LDKT) has become an established treatment for end-stage renal disease. Non-inferiority in the long-term graft function compared to ABO-compatible live-donor kidney transplantations (ABOc-LDKTs) has been shown. However, the assumed burden due to complications owing to increased immunosuppression inherent to ABOi-LDKTs has not yet been quantified. The aim of this study was to determine if ABOi-LDKT recipients suffer from additional morbidity and whether the resulting burden is justified. Methods: We retrospectively a

APA, Harvard, Vancouver, ISO, and other styles

21

Pandey, Soumya, Bobbie Rhodes-Clark, Rebecca Levy, and Terry Harville. "P219 Antibody-mediated rejection (AMR) not detected at autopsy in infant with ABO incompatible (ABOI) cardiac transplant despite increased levels of C1Q+ donor-specific antibodies (DSA) and possible previously-detected antibody-mediated rejection." Human Immunology 78 (September 2017): 216. http://dx.doi.org/10.1016/j.humimm.2017.06.279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Mahendran, A. O., S. Mohan, A. C. Watkins, et al. "Does Incompatibility Matter? Comparative Outcomes Following Treatment of Early AMR in ABO-Incompatible (Aboi) Renal Transplants." Transplantation Journal 94, no. 10S (2012): 1061. http://dx.doi.org/10.1097/00007890-201211271-02104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Collas, P., R. Fissore, and J. M. Robl. "Preparation of Nuclear Transplant Embryos by Electroportation." Analytical Biochemistry 208, no. 1 (1993): 1–9. http://dx.doi.org/10.1006/abio.1993.1001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cengiz Seval, Guldane, Nergis Ozturk, Sinem Civriz Bozdag, et al. "Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis." Blood 134, Supplement_1 (2019): 4504. http://dx.doi.org/10.1182/blood-2019-127651.

Full text

Abstract:

Introduction: Hemorrhagic cystitis (HC) is a serious and common complication of hematopoietic cell transplantation (HCT) affecting both allogeneic (alloHCT) and haploidentical HCT recipients. Early urinary bleeding after transplant is usually attributed to toxic effects of cyclophosphamide (Cy) or other agents used in the conditioning regimen or for graft-versus-host disease (GVHD) prevention. HC occurring beyond 3 to 4 weeks after HCT is usually attributed to BK polyoma virus or other viruses, e.g. cytomegalovirus or adenovirus. The aims of this study were to determine the incidence, risk fac

APA, Harvard, Vancouver, ISO, and other styles

25

Carmichael, G., E. S. Lee, C. Tormey, N. Yurtsever, B. Shah, and L. Bizzario. "Lost in the Ds: Unexplained Loss of Rh(D) Antigen Expression By Serological Testing In Two Patients." American Journal of Clinical Pathology 162, Supplement_1 (2024): S148. http://dx.doi.org/10.1093/ajcp/aqae129.329.

Full text

Abstract:

Abstract Introduction/Objective While the loss of ABOH antigens has been well documented, reduced-to-absent expression of the RHD antigen is comparatively rare. Here, we describe two cases with D antigen loss presenting associated clinical settings, smear results, and red blood cell (RBC) genotyping findings to elucidate this unusual phenomenon. Methods/Case Report Cases (n=2) were retrospectively reviewed based on discovery during routine serological testing in our Blood Bank. RhD blood typing was performed via gel methods [Grifols, Los Angeles, CA]. Clinical information and laboratory data w

APA, Harvard, Vancouver, ISO, and other styles

26

Cengiz Seval, Guldane, Atilla Uslu, Ekin Kircali, et al. "Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data." Blood 134, Supplement_1 (2019): 2019. http://dx.doi.org/10.1182/blood-2019-128750.

Full text

Abstract:

Introduction: Several studies have attempted to describe the characteristics associated with large granular lymphocytosis (LGL) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its clinical significance. However the clinical features of LGL lymphocytosis in the allo-HSCT setting is still sparse. The current study represents a detailed review of 667 patients transplanted in a single center with the objective to define the incidence of LGL lymphocytosis, to identify associations with transplant-related clinical parameters and to assess the impact on transplant related

APA, Harvard, Vancouver, ISO, and other styles

27

Ur Rahman, Khalil, Sumyyia Abbasi, Parvez Ahmed, et al. "Outcome of Induction Chemotherapy in Acute Lymphoblastic Leukemia in a Resource Constrained Setting." Blood 144, Supplement 1 (2024): 5871. https://doi.org/10.1182/blood-2024-212244.

Full text

Abstract:

Background: Treatment of acute leukemia requires advanced healthcare setup with availability of advanced diagnostic, blood components and chemotherapeutic agents. In resource constrained settings there are suboptimal facilities for treating acute leukemias leading to early death. Pathwel center of hematology and bone marrow transplant (PATHWEL) is a recently established nonprofit facility for diagnosis and management of blood diseases. This center has adopted certain measures like intensive human resource training, optimizing the use of blood components and chemotherapeutic agents to make the

APA, Harvard, Vancouver, ISO, and other styles

28

Sehn, Laurie H., Matthew J. Matasar, Christopher R. Flowers, et al. "Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study." Blood 134, Supplement_1 (2019): 4081. http://dx.doi.org/10.1182/blood-2019-123449.

Full text

Abstract:

Introduction: Antibody-drug conjugate polatuzumab vedotin (pola) targets CD79b on B-cell non-Hodgkin lymphoma. Cytopenias and peripheral neuropathy (PN) are typical pola-associated adverse events (AEs). We reported significantly higher positron emission tomography-complete response (PET-CR) rates and improved duration of response (DOR), progression-free survival (PFS) and overall survival (OS) with pola + bendamustine-rituximab (BR) vs BR in patients (pts) with R/R DLBCL (Sehn et al. ASH 2018). With an additional year of follow up, we report updated results for the Ph Ib/II DLBCL cohorts (NCT0

APA, Harvard, Vancouver, ISO, and other styles

29

Zinzani, Pier Luigi, Vladimir Melnichenko, Krimo Bouabdallah, et al. "Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study." Blood 136, Supplement 1 (2020): 42–43. http://dx.doi.org/10.1182/blood-2020-137080.

Full text

Abstract:

Introduction: No standard of care exists for patients (pts) with relapsed or refractory primary mediastinal B-cell lymphoma (rrPMBCL). As such, pts typically receive therapies recommended for diffuse large B-cell lymphoma, with poor prognosis. Similar to classical Hodgkin lymphoma, rrPMBCL tumors often overexpress the programmed death 1 (PD-1) ligands, PD-L1 and PD-L2. Data from the first full analysis of the phase 2 KEYNOTE (KN)-170 (NCT02576990) study showed that pembrolizumab provided effective and durable antitumor activity with a manageable safety profile in patients with rrPMBCL. These d

APA, Harvard, Vancouver, ISO, and other styles

30

Zinzani, Pier Luigi Luigi, Catherine Thieblemont, Vladimir Melnichenko, et al. "Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)." Blood 138, Supplement 1 (2021): 306. http://dx.doi.org/10.1182/blood-2021-148082.

Full text

Abstract:

Abstract Introduction: Similar to classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma (PMBCL) expresses high level of the programmed cell death 1 (PD-1) ligands: PD-L1 and PD-L2. Prior analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated that monotherapy with the PD-1 inhibitor pembrolizumab had effective antitumor activity and acceptable safety in relapsed/refractory (R/R) PMBCL, leading to FDA approval for adult patients with R/R PMBCL after ≥2 prior therapies. Long-term durability of response with PD-1 blockade in patients with PMBCL, especially those who a

APA, Harvard, Vancouver, ISO, and other styles

31

Sehn, Laurie H., Mark Hertzberg, Stephen Opat, et al. "Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension." Blood 136, Supplement 1 (2020): 17–19. http://dx.doi.org/10.1182/blood-2020-137078.

Full text

Abstract:

Introduction: Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting CD79b on B-cell non-Hodgkin lymphoma. In the randomized cohort of GO29365, a Phase [Ph] Ib/II study (NCT02257567; data cut-off: April 30, 2018), Pola plus bendamustine and rituximab (Pola+BR) improved progression-free survival (PFS) and overall survival (OS) compared with BR alone in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). The study met its primary endpoint, with an independent review committee (IRC)-assessed complete response (CR) rate of 40.0% with Pola+BR vs 17.5%

APA, Harvard, Vancouver, ISO, and other styles

32

Deng, Yun, Lukas Frischnknecht, Caroline Wehmeier, et al. "Pre-transplant donor specific antibodies in ABO incompatible kidney transplantation – data from the Swiss transplant cohort study." Frontiers in Immunology 15 (February 1, 2024). http://dx.doi.org/10.3389/fimmu.2024.1355128.

Full text

Abstract:

BackgroundLiving donor (LD) kidney transplantation in the setting of ABO blood group incompatibility (ABOi) has been previously reported to be associated with increased risk for antibody-mediated rejection (ABMR). It is however unclear if the presence of pre-transplant donor specific antibodies (DSA) works as an additive risk factor in the setting of ABOi and if DSA positive ABOi transplants have a significantly worse long-term outcome as compared with ABO compatible (ABOc) DSA positive transplants.MethodsWe investigated the effect of pre-transplant DSA in the ABOi and ABOc setting on the risk

APA, Harvard, Vancouver, ISO, and other styles

33

Hew, Eun Yee, Nicos Kessaris, Jelena Stojanovic, et al. "Successful ABO and HLA incompatible kidney transplantation in children in the UK." Pediatric Nephrology, June 13, 2022. http://dx.doi.org/10.1007/s00467-022-05583-5.

Full text

Abstract:

Abstract Background There is increasing evidence of good short-term and medium-term outcomes of ABO incompatible (ABOi) and HLA incompatible (HLAi) kidney transplantation with pre-transplant positive crossmatches in paediatric practice. However, there remain concerns regarding the higher risks of infective complications and antibody-mediated rejections. The aim of our study is to show longer-term follow-up on all ABOi and HLAi paediatric kidney transplant recipients (pKTR) in the UK. Methods Questionnaires specifying kidney transplant type, desensitisation requirement and kidney allograft func

APA, Harvard, Vancouver, ISO, and other styles

34

Saigal, Sanjiv. "ABO Incompatible Liver Transplantation: Current Status." ABO Incompatible Liver Transplantation: Current Status I, no. 3 (2024). http://dx.doi.org/10.62830/mmj1-3-13b.

Full text

Abstract:

Living donor liver transplant (LDLT) is a predominant form of liver transplant in countries with scarce availability of cadaveric donors. In East and South Asian countries, more than 80% of liver transplants are LDLT. Breaching of ABO barrier has led to further expansion of donor pools in these countries and ABO-incompatible (ABOi) LDLT constitutes a significant number of living donor liver transplants. One of the most important steps in ABOi LDLT is pretransplant desensitization to prevent ABO antibodies-related rejection and graft dysfunction. Desensitization is achieved by preoperative ritu

APA, Harvard, Vancouver, ISO, and other styles

35

Lemoine, Caroline P., Katherine A. Brandt, Mahima Keswani, and Riccardo Superina. "Outcomes after ABO incompatible pediatric liver transplantation are comparable to ABO identical/compatible transplant." Frontiers in Pediatrics 11 (May 31, 2023). http://dx.doi.org/10.3389/fped.2023.1092412.

Full text

Abstract:

BackgroundABO incompatible (ABOi) liver transplantation (LT) was initially associated with a higher incidence of vascular, biliary, and rejection complications and a lower survival than ABO compatible (ABOc) LT. Various protocols have been proposed to manage anti-isohemagglutinin antibodies and hyperacute rejection. We present our experience with a simplified protocol using only plasmapheresis.MethodsA retrospective review of all patients who received an ABOi LT at our institution was performed. Comparisons were made based on era (early: 1997–2008, modern: 2009–2020) and severity of disease (s

APA, Harvard, Vancouver, ISO, and other styles

36

Valentino, Pamela L., Patrick J. Healey, James D. Perkins, et al. "ABO Incompatible Grafts Are Associated With Excellent Outcomes in Pediatric Liver Transplant Recipients: An Important Resource to Reduce Waitlist Mortality." Pediatric Transplantation 29, no. 3 (2025). https://doi.org/10.1111/petr.70047.

Full text

Abstract:

ABSTRACTBackgroundLiver transplant (LT) waitlist mortality occurs in 10% of children; innovative strategies to expand access to LT can be lifesaving.MethodsOutcomes of ABO incompatible (ABOi) LT performed between 1999 and 2023 at a high‐volume center were compared to ABO compatible (ABOc) LT.Results25 ABOi LT were performed among 270 LT; 72% were listed with status 1/1A/1B or a median pediatric end‐stage liver disease/model for end‐stage liver disease of 40 (IQR 32,41). Time on the waitlist for ABOi recipients was shorter (median 11 days [IQR 4,46]) compared to ABOc (113 days [IQR 39,252], p &

APA, Harvard, Vancouver, ISO, and other styles

37

Wessels, E. U., J. Loveland, H. Maher, et al. "ABO-incompatible liver transplantation – exploring utilitarian solutions to restricted access and organ shortages: A single-centre experience from Johannesburg, South Africa." South African Medical Journal, April 24, 2024, e1211. http://dx.doi.org/10.7196/samj.2024.v114i3b.1211.

Full text

Abstract:

Background. Liver transplantation is the definitive management for severe acute liver failure refractory to supportive management, and end- stage chronic liver failure. Owing to a shortage of deceased liver donors, South Africa requires innovative techniques to broaden the donor pool. Objectives. This study evaluated the outcomes of the Wits Transplant Unit ABO-incompatible liver transplant (ABOi-LT) programme. Methods. This retrospective record review compared all adult and paediatric patients receiving ABO-compatible (ABOc) and ABO-incompatible (ABOi) liver transplants from January 2014 to D

APA, Harvard, Vancouver, ISO, and other styles

38

Li, Yamei, Yunying Shi, Tao Lin, et al. "P1740KINETICS OF B-CELL SUBSETS RECONSTITUTION FOLLOWING RITUXIMAB TREATMENT IN ABO-INCOMPATIBLE KIDNEY TRANSPLANT RECIPIENTS." Nephrology Dialysis Transplantation 35, Supplement_3 (2020). http://dx.doi.org/10.1093/ndt/gfaa142.p1740.

Full text

Abstract:

Abstract Background and Aims With the application of B-cell-depleting agent rituximab, plasmapheresis and powerful immunosuppression, ABO-incompatible kidney transplant recipients (ABOi-KT) have successfully overcome the ABO antibody barrier. As an important immune cell population, B cells are not only involved in antibody-mediated rejection, but also have been reported to have different immunoregulatory effects due to the existence of distinct B cell subsets. Therefore, comprehensively understanding the reconstitution of B-cell subsets in ABOi-KTRs is crucial to know the immune status that ma

APA, Harvard, Vancouver, ISO, and other styles

39

Shi, Yunying, Yamei Li, Tao Lin, et al. "P1745EFFECTS OF DESENSITIZATION THERAPY ON LYMPH NODES AND PERIPHERAL BLOOD TFH AND TFR CELLS IN ABO-INCOMPATIBLE KIDNEY TRANSPLANT RECIPIENTS." Nephrology Dialysis Transplantation 35, Supplement_3 (2020). http://dx.doi.org/10.1093/ndt/gfaa142.p1745.

Full text

Abstract:

Abstract Background and Aims Desensitization therapy has enabled successful transplantation of renal allografts across the ABO blood group barrier, which significantly expands the living donor pool. Whether the B cell depletion induced by rituximab would affect the proportions of peripheral blood (PB) and lymph nodes (LN) T follicular helper (Tfh) and T follicular regulatory (Tfr) cells, whose survival depends on B cells, in ABO-incompatible kidney transplant recipients (ABOi-KTRs) is unknown. Method PB and LN samples were simultaneously collected on the day of transplantation from 14 ABOi-KTR

APA, Harvard, Vancouver, ISO, and other styles

40

Bocchi, Federica, Isabelle Binet, Dela Golshayan, et al. "Impact of Repeated Non‐Fatal Infections on Quality of Life and Graft Function in ABO‐Incompatible Kidney Transplants." Transplant Infectious Disease, July 22, 2025. https://doi.org/10.1111/tid.70084.

Full text

Abstract:

ABSTRACTBackgroundKidney transplantation (KT) is the preferred treatment for kidney failure, with living donor KT (LDKT) offering better outcomes and improved quality of life (QOL) than deceased donor KT. ABO incompatibility (ABOi) once restricted LDKT, but desensitization protocols now enable ABOi LDKT, expanding the donor pool with favorable outcomes. However, added risks of ABOi remain debated. We examined the impact of repeated infections on graft loss and death in both ABO‐compatible (ABOc) and ABOi LDKT recipients.MethodsRetrospective, nationwide Swiss Transplant Cohort Study from May 20

APA, Harvard, Vancouver, ISO, and other styles

41

Guy, Pierre, Audrey Delas, Laure Esposito, et al. "Progression of histological lesions after ABO incompatible kidney transplantation." Frontiers in Immunology 13 (October 6, 2022). http://dx.doi.org/10.3389/fimmu.2022.969998.

Full text

Abstract:

Recent large meta-analyses suggested a poorer long-term patients’ and grafts’ outcomes after ABO incompatible (ABOi) living-donor kidney transplantation (LDKT) compared to ABO compatible LDKT. However, little is known about the long-term histological pattern after ABOi LDKT. We compared the histological features observed on protocol biopsies from 03/11 to 11/19 in 94 ABOi LDKT (including 14 with preformed Donor Specific Antibodies, pDSAs), 27 LDKT ABO compatible (ABOc) with pDSAs, and 21 ABOc without pDSAs) during the first five years post transplantation. During the first 5 years post-transpl

APA, Harvard, Vancouver, ISO, and other styles

42

Hu, Chih-Yao, Cheng-Yen Chen, Hsin-Lin Tsai, et al. "Insufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in ABO-incompatible living donor liver transplantation for acute liver failure." Journal of the Chinese Medical Association, January 22, 2025. https://doi.org/10.1097/jcma.0000000000001211.

Full text

Abstract:

Background: ABO-incompatible liver transplantation (ABOi LT) can now be successfully performed with standard pretransplant induction therapy. For patients with chronic end-stage liver disease (ESLD), ABOi LT can achieve long-term outcomes comparable to those of blood type-compatible (ABOc) LT. Outcomes of patients with acute liver failure (ALF) who undergo urgent transplantation surgery with a limited induction period should be further investigated. Methods: Between 2004 and 2023, adult patients who underwent living donor liver transplantation (LDLT) at Taipei Veterans General Hospital were en

APA, Harvard, Vancouver, ISO, and other styles

43

Heo, Ga Young, Minsun Jung, Honglin Piao, et al. "Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes." Frontiers in Immunology 15 (October 28, 2024). http://dx.doi.org/10.3389/fimmu.2024.1465851.

Full text

Abstract:

IntroductionABO-incompatible (ABOi) kidney transplantation (KT) has become an important option to overcome organ shortage. Plasmapheresis/rituximab-based desensitization therapy has successfully reduced anti-ABO antibody levels and suppressed antibody-mediated rejection (AMR) in ABOi KT. However, high titers of anti-ABO antibodies in some patients are refractory to standard desensitization, leading to loss of KT opportunities or AMR.MethodsEculizumab treatment was used an adjunctive therapy to rescue high-titer ABOi KT patients refractory to plasmapheresis/rituximab-based desensitization. Mole

APA, Harvard, Vancouver, ISO, and other styles

44

Strickland, Ashlyn, Dafne Andrea Chianella, Minoo Kavarana, and Andrew Savage. "ABO-incompatible Orthotopic Heart Transplant: A Case Report." Journal of ExtraCorporeal Technology, March 31, 2023. http://dx.doi.org/10.1051/ject/2023009.

Full text

Abstract:

Abstract: Background: ABOi heart transplant has become routine for the majority of children < 2 years old. An 8-month-old child with complex congenital heart disease presented to the Medical University of South Carolina Shawn Jenkins Children's Hospital in need of transplantation. Methods: This case report describes the use of ABOi transplantation and describes the details of the total exchange transfusion prior to cardiopulmonary bypass. Results: After a successful intraoperative total exchange transfusion following the ABOi protocol, the patients isohemagglutinin titers were 1 on post-ope

APA, Harvard, Vancouver, ISO, and other styles

45

Zhao, Daqiang, Lan Zhu, Shengyuan Zhang, et al. "Case Report: Successful ABO-Incompatible Deceased Donor Kidney Transplantation in an Infant Without Pre-transplant Immunological Treatment." Frontiers in Medicine 9 (March 2, 2022). http://dx.doi.org/10.3389/fmed.2022.838738.

Full text

Abstract:

ABO blood group antibodies have not been generated or are at low titer during early infancy. Therefore, in theory, ABO-incompatible kidney transplantation (ABOi KT) may be successfully achieved in small infants without any pre-transplant treatment. We report here the first ABO-incompatible deceased donor kidney transplantation (ABOi DDKT) in an infant. The recipient infant was ABO blood group O, and the donor group A. The recipient was diagnosed with a Wilms tumor gene 1 (WT1) mutation and had received peritoneal dialysis for 4 months prior to transplant. At 7 months and 27 days of age, the in

APA, Harvard, Vancouver, ISO, and other styles

46

Rosenthal, L. Lily, Tabea Katharina Spickermann, Sarah Marie Ulrich, et al. "Single center experience with ABO-incompatible and ABO-compatible pediatric heart transplantation." Frontiers in Transplantation 3 (October 10, 2024). http://dx.doi.org/10.3389/frtra.2024.1452617.

Full text

Abstract:

IntroductionThe aim of this study was to analyze the results after pediatric heart transplantation (pHTx) at our single center differentiating between ABO-incompatible (ABOi) and -compatible (ABOc) procedures.Methods and patientsWe retrospectively analyzed outcomes of ABO-incompatible HTx procedures performed at our center and compared the data to ABO-compatible HTx of the same era. Eighteen children (&lt;17 months) underwent pediatric HTx and seven of them underwent ABO-incompatible HTx between 2003 and 2015.ResultsMechanical circulatory support as bridge to transplant was necessary in 3/

APA, Harvard, Vancouver, ISO, and other styles

47

Matuschik, Laura, Gabriel Seifert, Katrin Lammich, et al. "Non-antigen-specific Immunoadsorption Is a Risk Factor for Severe Postoperative Infections in ABO-Incompatible Kidney Transplant Recipients." Transplant International 37 (March 14, 2024). http://dx.doi.org/10.3389/ti.2024.12263.

Full text

Abstract:

ABO-incompatible (ABOi) living kidney transplantation (KTx) is an established procedure to address the demand for kidney transplants with outcomes comparable to ABO-compatible KTx. Desensitization involves the use of immunoadsorption (IA) to eliminate preformed antibodies against the allograft. This monocentric retrospective study compares single-use antigen-selective Glycosorb® ABO columns to reusable non-antigen-specific Immunosorba® immunoglobulin adsorption columns regarding postoperative infectious complications and outcome. It includes all 138 ABOi KTx performed at Freiburg Transplant Ce

APA, Harvard, Vancouver, ISO, and other styles

48

Junker, Till, Thomas Volken, Gregor Stehle, et al. "Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study." Transfusion Medicine and Hemotherapy, January 18, 2023, 1–12. http://dx.doi.org/10.1159/000528261.

Full text

Abstract:

<b><i>Introduction:</i></b> Immunoadsorption (IA) of isohemagglutinins is an often-crucial procedure in preparation of major ABO blood group-incompatible living donor kidney transplantation (ABOi LDKT). Standard citrate-based anticoagulation during the procedure has potential disadvantages for distinct patient groups. In this study, we report our experience with an alternative anticoagulation scheme using heparin during IA for selected patients. <b><i>Methods:</i></b> We conducted a retrospective analysis of all patients who underwent IA with hep

APA, Harvard, Vancouver, ISO, and other styles

49

Nayebpour, Mehdi, Hanaa Ibrahim, Andrew Garcia, et al. "Increasing Access to Kidney Transplantation in African Americans and Asian Through Modification of Current Allocation Policy for A2 to B Kidney Transplants." Kidney360, November 21, 2023. http://dx.doi.org/10.34067/kid.0000000000000297.

Full text

Abstract:

Introduction: The rate of A2 to B incompatible (ABO-i) kidney transplant continues to be low despite measures in the new Kidney Allocation System (KAS) to facilitate such transplants. This paper shows how the number of ABO-i transplants could increase if KAS policies were utilized to their fullest extent through a boost in ABO-i priority points. Method: Predicting transplant outcomes using the Kidney Pancreas Simulated Allocation Model (KPSAM), preloaded with national data of 2010. We used this simulation to compare KAS to a new intervention in which priority equal to cPRA=100 has been given t

APA, Harvard, Vancouver, ISO, and other styles

50

Sharma, Sourabh, and Debabrata Mukherjee. "P1750IMMUNE-ADSORPTION COLUMNS IN ABOI INCOMPATIBLE RENAL TRANSPLANTATION: EXPERIENCE FROM DEVELOPING WORLD." Nephrology Dialysis Transplantation 35, Supplement_3 (2020). http://dx.doi.org/10.1093/ndt/gfaa142.p1750.

Full text

Abstract:

Abstract Background and Aims We present our experience of ABO-incompatible renal transplant using immunoadsorption (IA) columns. We have compared efficacy of two commercially available columns Method This single-center prospective study was conducted at Army Hospital Research and Referral, Delhi. All consecutive ABO-incompatible renal transplants from January 2014 to February 2018 were analyzed. Of 30 patients who underwent transplantations, 28 underwent antibody depletion with immunoadsorption columns. Of them, 14 cases were in the “Glycosorb group,” while 14 in the “Adsopak group.” Results T

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!